Pathobiology
Inhibition of Mammary Carcinoma Growth by Retinoidal Benzoic Acid DerivativesFontana J.A.a · Hobbs P.D.b · Dawson I.baUniversity of Maryland Cancer Center and Department of Medicine, University of Maryland, Baltimore, Md., and bLife Sciences Division, SRI International, Menlo Park, Calif., USA
Keywords: RetinoidsBreast carcinoma inhibition |
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: March 29, 1988
Accepted: May 16, 1988
Published online: October 07, 2008
Issue release date: 1988
Number of Print Pages: 10
Number of Figures: 0
Number of Tables: 0
ISSN: 1015-2008 (Print)
eISSN: 1423-0291 (Online)
For additional information: https://www.karger.com/PAT
Abstract
The growth of many breast carcinoma cell lines is inhibited by vitamin A, and derivatives as well as synthetic retinoids. New retinoidal derivatives have recently been synthesized. These retinoidal benzoic acid derivatives displayed enhanced potency in their ability to reverse hamster tracheal keratinization and inhibit ornithine decarboxylase induction in mouse epidermis. We therefore screened a series of analogues of these compounds for their ability to inhibit human breast carcinoma cell proliferation utilizing three estrogen receptor-positive and two estrogen receptor-negative cell lines. The compound (E)-4–2-(5,6,7,8)tetrahydro-5,5,8,8-tetramethyl-2-naphtalenyl)propenyl benzoic acid (Ro 1374–10) was approximately 2–3 orders of magnitude more potent than all-trans-retinoic acid in inhibiting breast carcinoma cell proliferation while the compound SRI-6409–40, which differs from Ro 1374–10 only by the position of a methyl group, was 50-fold more potent than Ro 1374–10. All of the compounds tested displayed were inactive against the estrogen receptor-negative breast carcinoma lines.
© 1988 S. Karger AG, Basel
Related Articles:
Article / Publication Details
Received: March 29, 1988
Accepted: May 16, 1988
Published online: October 07, 2008
Issue release date: 1988
Number of Print Pages: 10
Number of Figures: 0
Number of Tables: 0
ISSN: 1015-2008 (Print)
eISSN: 1423-0291 (Online)
For additional information: https://www.karger.com/PAT
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Get Permission